Successful ixazomib treatment for relapsed and refractory acute myeloid leukemia transformed from myelodysplastic syndrome

Successful ixazomib treatment for relapsed and refractory acute myeloid leukemia transformed from myelodysplastic syndrome

Abstract Elevated NF‐kB levels have been identified in primitive bone marrow cells from patients with MDS/AML, suggesting NF‐kB as a therapeutic target in MDS/AML. We herein describe an MDS patient ineligible for SCT who, following treatment with azacitidine and bortezomib, transformed to leukemia,...

Full description

Bibliographic Details
Main Authors: Satoko Oka, Kazuo Ono
Format: Article
Language:English
Published: Wiley 2021-06-01
Series:Clinical Case Reports
Subjects:
acute myelogenous leukemia
ixazomib
Myelodysplastic syndrome
NF‐κB
Online Access:https://doi.org/10.1002/ccr3.4287
Description
Summary:Abstract Elevated NF‐kB levels have been identified in primitive bone marrow cells from patients with MDS/AML, suggesting NF‐kB as a therapeutic target in MDS/AML. We herein describe an MDS patient ineligible for SCT who, following treatment with azacitidine and bortezomib, transformed to leukemia, but maintained complete remission after monotherapy with ixazomib.
ISSN:2050-0904

Similar Items